Ferritin Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instrument, Reagent, and Kits), By Application (Anaemia, Hemochromatosis, Lead Poisoning, Pregnancy, and Others), By End Use (Hospitals and Diagnostic Laboratories), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.67 Billion
CAGR (2026-2031)	7.59%
Fastest Growing Segment	Kits
Largest Market	North America
Market Size (2031)	USD 2.59 Billion

Market Overview

The Global Ferritin Testing Market will grow from USD 1.67 Billion in 2025 to USD 2.59 Billion by 2031 at a 7.59% CAGR. Ferritin testing is a clinical diagnostic method used to quantify serum ferritin levels, providing a definitive assessment of total body iron stores to detect anemia or iron overload. The global market is continually propelled by the increasing prevalence of nutritional deficiencies and the critical need for iron monitoring in managing chronic conditions such as renal failure. According to the American Society of Hematology, in 2024, the prevalence of iron deficiency among adolescent and young adult women in the United States was estimated to reach as high as 39%, reflecting the substantial demand for diagnostic intervention.

Despite these strong drivers, the market encounters a significant challenge regarding the high cost of automated immunoassay systems required for precise testing. This financial burden, combined with a scarcity of advanced laboratory infrastructure in emerging economies, limits the accessibility of ferritin testing and constrains market growth in developing regions.

Key Market Drivers

The rising global prevalence of iron deficiency anemia serves as a primary engine for market expansion, necessitating frequent diagnostic screening to prevent long-term health complications. The disconnect between overt anemia and latent iron deficiency significantly widens the potential testable population, driving the adoption of ferritin assays for routine assessment. According to the American Society of Hematology, November 2025, in the systematic review 'Prevalence of iron deficiency with or without anemia in adults', the pooled prevalence of iron deficiency across all ferritin thresholds was found to be 30%, indicating a vast under-diagnosed patient pool. This substantial prevalence underscores the critical need for accessible diagnostic intervention to manage iron stores effectively. Furthermore, according to the Centers for Disease Control and Prevention, in 2024, the overall prevalence of anemia in people aged two years and older was 9.3%, highlighting the baseline demand for hematological monitoring that supports the global testing market.

The rapid growth of the geriatric population susceptible to chronic diseases, particularly chronic kidney disease, further accelerates the demand for precise ferritin monitoring. In elderly patients with complex comorbidities, distinguishing between iron deficiency anemia and anemia of chronic disease is essential for appropriate therapeutic intervention. According to the Nutrition Journal, January 2025, in the study 'Association of iron deficiency with kidney outcome and all-cause mortality in chronic kidney disease patients without anemia', 27.2% of non-dialysis-dependent patients had ferritin levels at or below 100 ng/mL. This data emphasizes the necessity for vigilant iron store evaluation in this expanding demographic. As healthcare systems increasingly prioritize the management of chronic conditions to reduce hospital readmissions, the reliance on ferritin testing as a fundamental diagnostic tool in geriatric care continues to intensify.

Download Free Sample Report

Key Market Challenges

The primary impediment to the expansion of the Global Ferritin Testing Market is the prohibitive expense associated with automated immunoassay systems, compounded by a lack of adequate laboratory infrastructure in developing regions. Precise ferritin quantification requires advanced diagnostic platforms that demand substantial initial capital investment and significant ongoing operational funding. In emerging economies, where healthcare budgets are often restricted, this financial burden prevents the widespread installation of the necessary equipment, creating a barrier to entry that effectively locks out a large demographic of potential patients who require iron monitoring.

This economic strain is further intensified by the escalating costs of regulatory compliance and device maintenance, which manufacturers inevitably pass on to laboratories. According to MedTech Europe, in 2025, industry survey findings indicated that manufacturers of in vitro diagnostics are projected to incur maintenance and re-certification costs that are 70% higher than initial certification fees over a standard cycle. These rising costs increase the total ownership price of automated systems, rendering them financially unviable for resource-limited facilities. Consequently, the market struggles to penetrate high-need developing nations, directly hampering global revenue growth despite the rising prevalence of iron deficiency.

Key Market Trends

The proliferation of at-home and self-testing kits is fundamentally reshaping the market by decentralizing diagnostic access and empowering patients to monitor iron stores without visiting clinical laboratories. This trend is heavily supported by the expansion of direct-to-consumer digital sales channels, which allow individuals to order and receive diagnostic kits directly, bypassing traditional healthcare bottlenecks. The convenience of capillary blood collection combined with digital result delivery appeals to health-conscious demographics, effectively circumventing the infrastructure limitations of centralized testing. According to Quest Diagnostics, January 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company expanded its consumer-initiated test platform to include approximately 135 tests, covering critical categories such as micronutrient deficiencies, thereby broadening access to essential metabolic monitoring.

Simultaneously, the integration of smartphone-based diagnostic platforms is revolutionizing the speed and affordability of ferritin quantification, particularly in resource-limited settings. By leveraging the high-resolution imaging capabilities of standard mobile devices, developers are creating colorimetric analysis tools that eliminate the need for expensive, stationary spectrophotometers. These portable solutions utilize custom applications to analyze reaction changes on microfluidic strips, offering immediate clinical data in non-laboratory environments. According to the Cornell Chronicle, December 2024, in the article 'New Cornell tech to evaluate anemia to be used across India', a smartphone-based diagnostic technology named AnemiaPhone was formally transferred to the Indian Council of Medical Research to enable rapid, point-of-need screening for iron deficiency, illustrating the scalability of mobile-linked diagnostics.

Segmental Insights

The Kits segment represents the fastest-growing category in the Global Ferritin Testing Market, driven by a global shift towards point-of-care diagnostics and home-based healthcare. This expansion is fueled by the rising prevalence of anemia and iron deficiency disorders, necessitating frequent and accessible monitoring. Medical professionals increasingly rely on these self-contained diagnostic tools for their ease of use, rapid results, and ability to function outside traditional laboratory settings. Additionally, rigorous quality standards enforced by agencies such as the U.S. FDA ensure the reliability of these immunoassays, further boosting adoption rates across clinical and private sectors.

Regional Insights

North America maintains a dominant position in the global ferritin testing market, driven primarily by the high prevalence of anemia and iron deficiency disorders. This leadership is reinforced by well-developed healthcare infrastructure and substantial healthcare spending, particularly within the United States. The region benefits significantly from the strong presence of major diagnostic manufacturers, ensuring the widespread availability of testing kits. Furthermore, streamlined product approvals by the U.S. Food and Drug Administration facilitate the rapid adoption of diagnostic technologies. Consequently, a growing geriatric population and rising awareness of blood health continue to strengthen regional market performance.

Recent Developments

• In September 2024, LifeLabs implemented new clinical decision limits for ferritin testing across its network in Ontario to better align with updated guidelines for diagnosing iron deficiency. The organization replaced the previous reference intervals with specific cut-off values, establishing a ferritin level of less than 30 micrograms per litre as the threshold for diagnosing iron deficiency in adults. This operational update was intended to standardize reporting and assist healthcare providers in identifying iron deficiency more effectively, ensuring that patients with low iron stores received timely and appropriate clinical management.
• In August 2024, FeBI Technologies, in collaboration with the Florey Institute of Neuroscience and Mental Health and the University of Melbourne, announced the development of a breakthrough quantum sensing technology for measuring iron levels. Unlike traditional ferritin tests which can be influenced by inflammation, this new method, known as FeBI (Ferritin Bound Iron), utilized diamond-based quantum sensors to detect the specific magnetic signature of iron atoms within ferritin proteins. The company aimed to deploy this innovation to pathology laboratories to provide a more accurate assessment of iron deficiency, particularly in patients with chronic health conditions where standard ferritin tests often yield ambiguous results.
• In July 2024, Quest Diagnostics announced a definitive agreement to acquire LifeLabs, a leading Canadian provider of community laboratory tests and diagnostics, in a transaction valued at approximately CAD 1.35 billion. This strategic acquisition was designed to expand the presence of Quest Diagnostics in the North American diagnostic market, granting it access to LifeLabs' extensive network of service centers and processing facilities. The collaboration aimed to improve access to diagnostic innovation, including essential routine testing such as ferritin screening, by combining the operational strengths and clinical expertise of both organizations.
• In March 2024, Beckman Coulter Diagnostics received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Access Ferritin assay on the DxI 9000 Access Immunoassay Analyzer. This approval allowed the new high-throughput instrument to expand its menu of available tests, providing laboratories with a precise solution for measuring ferritin levels to aid in the diagnosis of iron deficiency anemia and iron overload. The clearance demonstrated the company's commitment to migrating its critical immunoassays to its latest platform, ensuring enhanced workflow efficiency and reliability for clinical laboratories managing high testing volumes.

Key Market Players

• Eurolyser Diagnostica GmbH
• Cortez Diagnostics Inc.
• Thermo Fisher Scientific Inc.
• Biomérieux S.A
• Aviva Systems Biology Corporation
• Abnova Corporation
• CTK Biotech Inc.
• Randox Laboratories Ltd.
• Guangzhou Wondfo Biotech Co., Ltd.
• F. Hoffmann-La Roche Ltd.

By Product	By Application	By End Use	By Region
Instrument Reagent and Kits	Anaemia Hemochromatosis Lead Poisoning Pregnancy and Others	Hospitals and Diagnostic Laboratories	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Ferritin Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Ferritin Testing Market, By Product:

• Instrument
• Reagent
• and Kits

• Ferritin Testing Market, By Application:

• Anaemia
• Hemochromatosis
• Lead Poisoning
• Pregnancy
• and Others

• Ferritin Testing Market, By End Use:

• Hospitals and Diagnostic Laboratories

• Ferritin Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE